NASDAQ:LNTH Lantheus - LNTH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $55.84 +1.19 (+2.18%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$55.00▼$55.9450-Day Range$47.76▼$62.0852-Week Range$23.51▼$87.47Volume539,099 shsAverage Volume940,912 shsMarket Capitalization$3.84 billionP/E Ratio37.48Dividend YieldN/APrice Target$102.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Lantheus MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside84.1% Upside$102.80 Price TargetShort InterestHealthy5.12% of Float Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment0.59Based on 14 Articles This WeekInsider TradingSelling Shares$1.11 M Sold Last QuarterProj. Earnings Growth11.05%From $3.53 to $3.92 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.93 out of 5 starsMedical Sector55th out of 1,048 stocksDiagnostic Substances Industry1st out of 17 stocks 3.5 Analyst's Opinion Consensus RatingLantheus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $102.80, Lantheus has a forecasted upside of 84.1% from its current price of $55.84.Amount of Analyst CoverageLantheus has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.12% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lantheus has recently decreased by 5.48%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLantheus has received a 61.07% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Diagnostic radiopharmaceuticals", and "Therapeutic radiopharmaceuticals" products. See details.Environmental SustainabilityThe Environmental Impact score for Lantheus is -1.67. Previous Next 3.1 News and Social Media Coverage News SentimentLantheus has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Lantheus this week, compared to 5 articles on an average week.Search Interest13 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.MarketBeat Follows13 people have added Lantheus to their MarketBeat watchlist in the last 30 days. This is an increase of 160% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,105,945.00 in company stock.Percentage Held by InsidersOnly 1.60% of the stock of Lantheus is held by insiders.Percentage Held by Institutions97.62% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Lantheus are expected to grow by 11.05% in the coming year, from $3.53 to $3.92 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 37.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 37.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.10.Price to Book Value per Share RatioLantheus has a P/B Ratio of 8.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lantheus (NASDAQ:LNTH) StockLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.Read More Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Stock News HeadlinesJanuary 24, 2023 | finance.yahoo.comHow Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 83.92%January 24, 2023 | finance.yahoo.comWill Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?January 26, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 24, 2023 | americanbankingnews.comSVB Leerink Comments on Lantheus Holdings, Inc.'s FY2022 Earnings (NASDAQ:LNTH)January 23, 2023 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) Receives $101.00 Average Price Target from BrokeragesJanuary 20, 2023 | americanbankingnews.comLantheus Holdings, Inc. (NASDAQ:LNTH) CAO Andrea Sabens Sells 386 SharesJanuary 13, 2023 | finance.yahoo.comAre Medical Stocks Lagging Aurora Cannabis (ACB) This Year?January 6, 2023 | finance.yahoo.comLantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should KnowJanuary 26, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 6, 2023 | finance.yahoo.comDown -8.54% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)January 6, 2023 | finance.yahoo.comMany Would Be Envious Of Lantheus Holdings' (NASDAQ:LNTH) Excellent Returns On CapitalJanuary 4, 2023 | finance.yahoo.comLantheus to Present at the J.P. Morgan 2023 Healthcare ConferenceDecember 29, 2022 | finance.yahoo.comDown -21.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)December 27, 2022 | finance.yahoo.comIs Lantheus (LNTH) Outperforming Other Medical Stocks This Year?December 12, 2022 | finance.yahoo.comLantheus Grants Rights for the Use of its Microbubbles to SonoThera for its Ultrasound-Guided Nonviral Gene Therapy PlatformDecember 9, 2022 | finance.yahoo.comLantheus Holdings (LNTH) Loses 10.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerDecember 2, 2022 | finance.yahoo.comWall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 64%: Here's is How to TradeNovember 29, 2022 | finance.yahoo.comLantheus Holdings' (NASDAQ:LNTH) three-year earnings growth trails the impressive shareholder returnsNovember 29, 2022 | finance.yahoo.comLantheus Announces Appointment of Amanda Morgan as Senior Vice President, CommercialNovember 28, 2022 | finance.yahoo.comLantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPANovember 18, 2022 | finance.yahoo.comThese 3 Stocks Are Crushing the Market. Wall Street Thinks They Can Soar at Least 78% Higher.November 9, 2022 | finance.yahoo.comLantheus to Present at the Jefferies London Healthcare ConferenceNovember 9, 2022 | finance.yahoo.comLantheus Holdings Third Quarter 2022 Earnings: Beats ExpectationsOctober 27, 2022 | finance.yahoo.comLantheus Holdings (LNTH) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseOctober 21, 2022 | finance.yahoo.comLantheus Holdings (LNTH) Gains But Lags Market: What You Should KnowOctober 20, 2022 | benzinga.comLantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m - BenzingaOctober 20, 2022 | finance.yahoo.comLantheus to Host Third Quarter 2022 Earnings Conference Call and Webcast on November 3, 2022, at 8:00 a.m. Eastern TimeSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Email Address LNTH Company Calendar Last Earnings11/03/2022Today1/26/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNTH CUSIPN/A CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees612Year FoundedN/APrice Target and Rating Average Stock Price Forecast$102.80 High Stock Price Forecast$120.00 Low Stock Price Forecast$91.00 Forecasted Upside/Downside+84.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)$1.49 Trailing P/E Ratio37.48 Forward P/E Ratio15.82 P/E GrowthN/ANet Income$-71,280,000.00 Net Margins13.35% Pretax Margin20.21% Return on Equity37.77% Return on Assets21.13% Debt Debt-to-Equity Ratio0.24 Current Ratio2.13 Quick Ratio1.98 Sales & Book Value Annual Sales$425.21 million Price / Sales9.04 Cash Flow$1.31 per share Price / Cash Flow42.67 Book Value$6.86 per share Price / Book8.14Miscellaneous Outstanding Shares68,832,000Free Float67,731,000Market Cap$3.84 billion OptionableOptionable Beta0.78 Key ExecutivesMs. Mary Anne Heino (Age 63)CEO, Pres & Director Comp: $2.15MMr. Robert J. Marshall Jr. (Age 56)CFA, Chief Financial Officer Comp: $905.94kMr. Paul M. Blanchfield (Age 42)Chief Operating Officer Comp: $734.54kMr. Daniel M. Niedzwiecki (Age 46)Sr. VP, Gen. Counsel & Corp. Sec. Comp: $627.1kMr. Etienne Montagut (Age 48)Chief Bus. Officer Comp: $607.99kMs. Andrea Sabens (Age 44)Chief Accounting Officer Ms. Dorothy BarrSr. VP of Manufacturing & Technical OperationsMr. Mark Richard KinarneySr. Director of Investor RelationsMs. Linda S. Lennox (Age 57)VP of Corp. Communications & Chief of Staff Melissa DownsDirector of Corp. CommunicationsMore ExecutivesKey CompetitorsNeogenNASDAQ:NEOGIntellia TherapeuticsNASDAQ:NTLACelldex TherapeuticsNASDAQ:CLDXQuidelOrthoNASDAQ:QDELMyriad GeneticsNASDAQ:MYGNView All CompetitorsInsiders & InstitutionsComerica BankBought 27,291 shares on 1/26/2023Ownership: 0.295%Strs OhioBought 1,100 shares on 1/26/2023Ownership: 0.034%Campbell Newman Asset Management Inc.Bought 21,221 shares on 1/26/2023Ownership: 0.031%Oregon Public Employees Retirement FundSold 2,487 shares on 1/26/2023Ownership: 0.029%Dupont Capital Management CorpSold 5,102 shares on 1/26/2023Ownership: 0.003%View All Insider TransactionsView All Institutional Transactions LNTH Stock - Frequently Asked Questions Should I buy or sell Lantheus stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LNTH shares. View LNTH analyst ratings or view top-rated stocks. What is Lantheus' stock price forecast for 2023? 5 brokers have issued 12 month target prices for Lantheus' shares. Their LNTH share price forecasts range from $91.00 to $120.00. On average, they predict the company's share price to reach $102.80 in the next twelve months. This suggests a possible upside of 84.1% from the stock's current price. View analysts price targets for LNTH or view top-rated stocks among Wall Street analysts. How have LNTH shares performed in 2023? Lantheus' stock was trading at $50.96 at the beginning of the year. Since then, LNTH stock has increased by 9.6% and is now trading at $55.84. View the best growth stocks for 2023 here. Are investors shorting Lantheus? Lantheus saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 3,450,000 shares, a drop of 5.5% from the December 31st total of 3,650,000 shares. Based on an average daily volume of 1,130,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 5.1% of the shares of the company are short sold. View Lantheus' Short Interest. When is Lantheus' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our LNTH earnings forecast. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) released its quarterly earnings results on Thursday, November, 3rd. The medical equipment provider reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.15. The medical equipment provider earned $239.29 million during the quarter, compared to analysts' expectations of $228.52 million. Lantheus had a net margin of 13.35% and a trailing twelve-month return on equity of 37.77%. What guidance has Lantheus issued on next quarter's earnings? Lantheus issued an update on its fourth quarter 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of $0.95-$0.98 for the period, compared to the consensus EPS estimate of $0.86. The company issued revenue guidance of $243.00 million-$247.00 million, compared to the consensus revenue estimate of $238.01 million. What is Mary Anne Heino's approval rating as Lantheus' CEO? 4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lantheus investors own include (MBBYF) (MBBYF), Energy Transfer (ET), Paratek Pharmaceuticals (PRTK), Catalyst Pharmaceuticals (CPRX), Amicus Therapeutics (FOLD), Anavex Life Sciences (AVXL), Exelixis (EXEL), Gerdau (GGB), Pieris Pharmaceuticals (PIRS) and Abeona Therapeutics (ABEO). When did Lantheus IPO? (LNTH) raised $75 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 7,900,000 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. What is Lantheus' stock symbol? Lantheus trades on the NASDAQ under the ticker symbol "LNTH." Who are Lantheus' major shareholders? Lantheus' stock is owned by a variety of retail and institutional investors. Top institutional investors include Reinhart Partners Inc. (0.84%), Congress Asset Management Co. MA (0.50%), Allspring Global Investments Holdings LLC (0.45%), Assenagon Asset Management S.A. (0.45%), Peregrine Capital Management LLC (0.39%) and Comerica Bank (0.30%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Julie Mchugh, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lantheus' stock price today? One share of LNTH stock can currently be purchased for approximately $55.84. How much money does Lantheus make? Lantheus (NASDAQ:LNTH) has a market capitalization of $3.84 billion and generates $425.21 million in revenue each year. The medical equipment provider earns $-71,280,000.00 in net income (profit) each year or $1.49 on an earnings per share basis. How many employees does Lantheus have? The company employs 612 workers across the globe. How can I contact Lantheus? Lantheus' mailing address is 331 TREBLE COVE ROAD, NORTH BILLERICA MA, 01862. The official website for the company is www.lantheus.com. The medical equipment provider can be reached via phone at (978) 671-8001, via email at ir@lantheus.com, or via fax at 978-671-8860. This page (NASDAQ:LNTH) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.